Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Product Sales: $28.9 billion for 2025, up 1% YoY, exceeding guidance of $28.4-$28.7 billion. Excluding Vecluri, sales were $28 billion, a 4% increase.

Q4 Product Sales: $7.9 billion, a 5% increase YoY; $7.7 billion excluding Vecluri, up 7% YoY.

HIV Business: Record sales of $20.8 billion for 2025, up 6% YoY, driven by Biktarvy and Descovy.

Operating Margin: 45% for 2025, with a product gross margin of 86.4%.

Non-GAAP EPS: $8.15, in line with guidance of $8.5-$8.25.

Shareholder Returns: $5.9 billion returned, including $1.9 billion in share repurchases.

2Strategic Updates and Business Highlights

HIV Portfolio Growth: Biktarvy sales reached $14.3 billion, up 7% YoY. The new injectable HIV prevention drug, YES2GO, launched successfully with $150 million in sales for 2025 and is expected to reach $800 million in 2026.

Liver Disease: Sales for liver treatments grew 6% YoY to $3.2 billion, driven by Libdelzi's adoption.

Oncology: Trodelvy sales increased 6% YoY to $1.4 billion, with positive phase three trial results boosting demand.

Pipeline Progress: Gilead has a robust pipeline with multiple upcoming launches and phase three updates expected in 2026, including Trodelvy in first-line metastatic breast cancer and Anidocel for multiple myeloma.

3Forward Guidance and Outlook

2026 Guidance: Total product sales expected between $29.6 billion and $30 billion. Base business sales projected to grow 4-5% YoY.

HIV Sales Growth: Anticipated at 6% for 2026, with YES2GO expected to contribute significantly.

Cell Therapy Decline: Kite revenue expected to decline approximately 10% in 2026 due to competitive pressures.

Operating Margin: Expected to remain strong, with continued focus on expense management.

4Bad News, Challenges, or Points of Concern

Vecluri Sales Decline: Revenue fell 49% YoY to $911 million due to reduced COVID-19 hospitalizations.

Competitive Pressures: Cell therapy sales are facing ongoing competition, impacting revenue forecasts.

Policy Headwinds: Anticipated 2% headwind to growth in 2026 due to drug pricing agreements and changes to the Affordable Care Act.

Market Dynamics: Transitioning from oral to injectable therapies may present logistical challenges and slower adoption rates.

5Notable Q&A Insights

YES2GO Growth: Management expressed optimism about YES2GO's potential, highlighting strong payer coverage and a direct-to-consumer campaign to drive awareness. However, they acknowledged the need for careful navigation of logistics in a shift to injectables.

Anidocel Market Entry: Confidence in a second-half 2026 launch was noted, with expectations of becoming a market leader due to its efficacy profile.

Trodelvy Off-Label Use: There are indications of off-label use in first-line settings, supported by positive trial results and NCCN recommendations.

Market Expansion: Discussions on the potential for new therapies, including a once-yearly injectable for HIV, were highlighted as significant opportunities for broadening patient access. Overall, Gilead Sciences, Inc. reported solid financial performance in 2025, driven by strong growth in its HIV portfolio and promising pipeline developments. However, challenges related to competitive pressures and policy changes pose risks to future growth.